Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 2 November 2026.
Announcements
1,179
Total raised
£24.7B
disclosed amounts
This month
£9.0M
raised so far
Creandum led the Series A round with participation from Peter Thiel, firstminute, Seedcamp, Hambro Perks and Amino Collective.
"Clinical trials are the biggest bottleneck to improving human health. We deliver clinical trials three times faster than the industry standard, working with biotech pioneers to get new treatments to patients more quickly."
The oversubscribed round was led by FlatzHoffmann with participation from new and existing investors to scale operations in North America.
"Our newly set up fund seeks to support technology companies with proven business models and a lasting environmental impact,"
The Series A round was co-led by S2G Ventures and SOUNDwaves to support commercial expansion and technology scaling.
"The combined support and expertise of our investors enables us to accelerate our work, moving beyond laundry into industrial-scale applications of our technology, and drive globally meaningful reductions in micropollutant emissions with confidence and speed."
The investment was led by Gresham House Ventures and will be used to scale technology and sales functions.
"Mable’s mission has always been to design therapy that puts children at its core, giving them the best chance to reach their full potential. Our pioneering technology has already helped thousands of families across the UK, and with this investment by Gresham House Ventures we can take this support even further."
The investment round was led by Archangels to help the life science firm advance its cell analysis platform.
"We are uniquely positioned in harnessing the power of consumer electronics technology to meet the emerging, complex needs of the bioprocess industry. On the back of a very successful year for Cytomos, this new funding will now allow us to scale up our engagement with industry partners. We truly believe that, through our CDS technology, we offer a powerful platform which will help the scientific community bring novel therapies to market faster and radically reduce costs by making better informed, game-changing decisions a lot earlier."
